Review Papers Against Their Own Results

What the paper does

The article is a narrative review that synthesizes prior literature to argue that neutrophils are central to tumor microenvironment biology and that modulating neutrophil phenotype and functions (promote N1, limit N2, manipulate NETs) could improve outcomes of immune checkpoint inhibitors and other cancer immunotherapies. It also suggests lifestyle and nutritional modifiers may influence neutrophil behavior and therefore treatment responses Khansari

Strengths

• Clear conceptual framing of neutrophil plasticity (N1 vs N2) and NETosis as double-edged processes in cancer immunity Neutrophil
• Practical translational suggestions (CXCR2/CXCL axis, NET targeting, NLR monitoring) that align with ongoing preclinical and clinical research pathways Therapy

Major limitations and important caveats

1. No systematic method reported — the piece is a narrative mini-review with no PRISMA or explicit search/inclusion/exclusion criteria. That raises selection bias risk and limits reproducibility Khansari
2. Sparse citation of high-quality human clinical data — many mechanistic claims and translational suggestions (dietary manipulations, NET promotion to help ICIs) are speculative and not substantiated with randomized clinical trials in the review text. This is a critical translational gap: reviews that propose clinical actions should anchor them to clinical trial evidence or explicitly label them as hypotheses Dietary
3. Over-generalization across tumor types and species — neutrophil roles vary across cancers (e.g., PDAC, NSCLC, breast) and models; the review often extrapolates mechanisms observed in murine models or specific tumors to all solid tumors without weighting evidence by tumor type or model limitations General
4. Low reference transparency — the published document contains few indexed, peer-reviewed references in its reference list (reference count reported as zero in extracted metadata), undermining confidence in literature coverage and source quality for many claims Reference
5. Potential for recommendation harm if misapplied — suggesting dietary or stress interventions to modulate neutrophils without clinical safety data may lead to inappropriate patient guidance; the review should have explicitly urged clinical trials before translational uptake Call

Where the review aligns or departs from contemporary evidence

Independent, higher quality recent reviews and primary studies show neutrophils are indeed heterogeneous and can both impair and support anti-tumor immunity; NETs are robustly associated with poor outcomes in multiple analyses, and targeting neutrophil recruitment or NETs is an active translational area — the Khansari review summarizes these themes but does not sufficiently weight the clinical evidence nor specify when preclinical findings are preliminary Neutrophil

Systematic meta-analyses show elevated NET markers associate with worse survival across cancers (meta-analysis and reviews through 2023–2025). That supports Khansari's emphasis on NETs but cautions that NETs more often correlate with poor outcomes than with therapy-enhancing functions in clinical series NETs

Specific improvements that would make this review more scientifically useful

• Provide systematic search methods (databases, date ranges, inclusion/exclusion criteria) or convert to a scoping review to transparently capture evidence strength across tumor types.
• Include a table stratifying evidence by model system (human tissue, clinical cohorts, murine models) and by cancer type to avoid overgeneralization.
• Explicitly rate strength of evidence for each translational proposal (e.g., CXCR2 blockade, DNase to degrade NETs, neutrophil adoptive transfer), and cite clinical trials or trial identifiers when available.
• Distinguish between measurable biomarkers (NLR, MPO-DNA, H3Cit) with clinical validation and speculative lifestyle recommendations (ketogenic diet) and avoid implying clinical readiness.
• Declare conflicts of interest and list funding; current metadata shows none reported and the reference list count is zero, which should be corrected for transparency.

High value experiments and clinical studies the field needs (prioritized)

1. Prospective cohort studies linking pretherapy NET markers (MPO-DNA, H3Cit) and NLR with ICI outcomes across tumor types, with multivariable adjustment for stage and systemic inflammation markers (CRP) — to evaluate prognostic vs predictive value NLR
2. Randomized controlled trials testing NET inhibition (e.g., PAD4 inhibitors or systemic DNase) added to standard ICI in cancers with high NET burden (guided by baseline NET assay) to test safety and efficacy.
3. Mechanistic human ex vivo assays: co-culture tumor-infiltrating lymphocytes with TANs from matched tumors to map suppressive pathways (arginase, ROS, PD-L1) and identify druggable nodes.
4. Carefully controlled nutritional intervention trials in patients receiving immunotherapy (pilot RCTs) with neutrophil polarization and systemic inflammation as preplanned mechanistic endpoints before clinical recommendations are made.

Quick evidence map extracted from the review (what it asserts vs evidence quality)

Next actions you can take (one click)

Author reviews

Conclusions and confidence

Khansari 2023 provides a useful conceptual primer that correctly highlights neutrophil plasticity and NET biology as important in cancer immunology; however, because it is a narrative mini-review with minimal referenced clinical data and no systematic methods, its translational recommendations should be treated as hypotheses requiring rigorous clinical testing rather than practice guidance Khansari

Overall confidence in this critique: 8/10 (I am confident the paper is a nonrigorous narrative review; clinical claims are speculative and need stronger evidence)